Responses
Rheumatoid arthritis
Original research
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
Compose a Response to This Article
Other responses
No responses have been published for this article.